Virtual variety is guaranteed

In talking to virtual biotech experts, one learns quickly that almost everyone in this game takes slightly or drastically different approaches to building their companies. Some favor certain tech tools, while others innovate with their business models. Nimbus, for example, has a corporate structure that supports the formation of multiple LLCs to tackle specific targets and offers multiple exit opportunities to investors. AstraZeneca's ($AZN) iMed has taken some of the tech insights that went into Chorus and then added in some other components based on the needs of a neuroscience R&D venture.

Please feel free to chime in with any additional insights that could help biotech pros with their own virtual business ambitions.

Virtual variety is guaranteed

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.